



# OXFORD-HARRINGTON RARE DISEASE CENTRE

DELIVERING CURES FOR RARE DISEASES

## IMPACT-DRIVEN MISSION

The Oxford-Harrington Rare Disease Centre (OHC) is a transatlantic initiative to develop novel treatments for rare diseases, for which therapeutic options are severely lacking. The OHC leverages a network of researchers from premier academic medical centres in the United Kingdom, United States, and Canada. Our goal is to advance 40 drugs into clinical trials in the next 10 years, targeting multiple approvals in key markets.

## WORLD-LEADING STRENGTHS COMBINED



### Harrington Discovery Institute

- Globally-recognized drug development model
- 201 medicines in the making
- 39 companies launched
- 21 medicines in the clinic
- 15 licenses to pharma

### University of Oxford

- #1 in the world for medicine
- Over 300 spin-outs
- Global research in 40 countries
- Over £789 million annual research income
- Over 8,000 research outputs per year

## GLOBAL NEED

10,000+

distinct types  
of rare diseases

400 MILLION

people worldwide live  
with a rare disease

<5%

of rare diseases have  
approved treatments

1 IN 2

patients diagnosed with  
a rare disease is a child



## IMPROVING THE STANDARD OF CARE

The OHC advances breakthrough discoveries out of academic labs and into the clinic and moves them towards new drug approvals in order to improve the lives of patients living with rare diseases.



Projects entering the OHC may qualify for additional funding to accelerate drug development, in addition to receiving:

- Grant funding
- Drug and business development support
- Facilitated access to funders, contract research organizations, patient organizations, and a nucleic acid therapy facility
- Invitation to present at the Oxford-Harrington Rare Disease Centre Symposium or Harrington Discovery Institute Scientific Symposium

## OHC THERAPEUTICS ACCELERATOR

The OHC utilizes a unique non-profit/for-profit model to accelerate the development of new rare disease treatments.

**INNOVATOR NETWORK**

Annual call for proposals to academic medical centres in UK, US, and Canada



**PHILANTHROPIC SUPPORT**

Funding, drug & business development expertise



**CATALYTIC CAPITAL**

Co-investment, spin-out companies, commercial partners



Drugs in clinical trials

## PARTNERS



[OxfordHarrington.org](http://OxfordHarrington.org)